Genentech/Tanox/Ciba to combine anti-IgE antibody development efforts.
Executive Summary
GENENTECH/TANOX/CIBA TO COMBINE ANTI-IGE ANTIBODY DEVELOPMENT for the treatment of allergies and allergic asthma as part of a July 9 settlement of litigation between Genentech and Tanox. Ciba is Tanox' partner for the anti-immunoglobulin E antibody research project under a 1990 agreement. The three companies plan to reach a definitive development agreement in the next six months.